Citation only
via OpenAlex
P3‐016: Chronic administration of CHF5074, a novel γ‐secretase modulator, prevents brain neurodegeneration in aged Alzheimer's disease transgenic mice
Sandra Sivilia, Luca Lorenzini, Alessandro Giuliani, Mercedes Fernández, Marco Gusciglio, Vladimiro Pietrini, Maria Francesca Baroc, Gino Villetti, Bruno Pietro Imbimbo, Laura Calzà, Luciana Giardino
Alzheimer s & Dementia · 2011
Abstract
CHF5074, a new gamma-secretase modulator, has been shown to inhibit brain plaque deposition and attenuate or reverse associated memory deficits in different transgenic mouse models of Alzheimer's disease. We evaluated the effect of CHF5074 chronic administration on molecular, cellular and anatomical indices of brain atrophy. Five-month-old Tg2576 mice and their wild-type littermates were treated with CHF5074 in the diet (125 or 375 ppm equivalent to about 20 and 60 mg/Kg/day) or vehicle for 13 months. At the end of the treatment, brain areas were weighed and measured, and the expression of synaptophysin, cyclin A, intracellular APP/Abeta, plaque load, activated microglia were evaluated with immunohistochemistry and quantitative image analysis. Cognitive performance was measured with the object recognition test. Compared to wild-type mice, Tg2576 mice showed a lower body weight gain curve (-26.3±4.4%, p<0.0001) but a higher brain/body weight ratio (2.14±0.08% vs 1.66±0.04%, p< 0.0001). CHF5074 long-term treatment normalized this ratio in Tg2576 mice (2.04±0.07% and 1.96±0.05% in the low and high dose groups, respectively). Compared to vehicle-treated Tg2576 mice, CHF5074 treatments significantly lowered intraneuronal APP/Abeta stained with 6E10 anti-Abeta (1-16) monoclonal antibody (-33.5±7.3%, p< 0.01 and -27.1±4.9%, p< 0.01). Amyloid burden was also reduced significantly by both CHF5074 dose treatments in both cortex (-61.0±5.1% and -48.2±8.9%) and hippocampus (-52.3±9.4% and -64.9±8.1%). Activated microglia in hippocampus was also significantly reduced by CHF5074 hippocampus (-53.7±3.8% and -47.7±4.2%). In transgenic mice there was a significant 41.3±3.6% reduction compared to wild-type animals in synaptophysin-immunoreactivity in the cerebral cortex and both CHF5074 doses reversed this deficit. Cyclin A immunoreactivity was identified in NeuN-positive cells, which defines mature neurons. The number of CycA-positive cells over the total number of NeuN-positive neurons was counted in layer II-III of the medial cerebral cortex. While in wild-type mice the percentage of neurons expressing CycA was 8.6±1.5%, we found that 47.8±3.3% of neurons expressing CycA in Tg2576 mice. Treatment with CHF5074 reduced this value to 17.6±1.5% (p < 0.01) and 17.8±1.3% (p< 0.01) in the 20 mg/kg/day and 60 mg/kg/day groups, respectively. CHF5074 dose-dependently reversed object recognition memory deficit in transgenic mice. This study indicated that CHF5074 affects several molecular and cellular neuronal parameters associated to the aging of the Tg2576 mice's brain. The normalization of the brain volume of the transgenic mice treated with the drug could be related to the reduction of the age-associated neuroinflammation and/or to the marked reduction of the amyloid plaque burden.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.jalz.2011.05.1455
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Sivilia, S., Lorenzini, L., Giuliani, A., Fernández, M., Gusciglio, M., Pietrini, V., Baroc, M.F., Villetti, G., Imbimbo, B.P., Calzà, L., & Giardino, L. (2011). P3‐016: Chronic administration of CHF5074, a novel γ‐secretase modulator, prevents brain neurodegeneration in aged Alzheimer's disease transgenic mice. <em>Alzheimer s & Dementia</em>. https://doi.org/10.1016/j.jalz.2011.05.1455
Vancouver
Sivilia S, Lorenzini L, Giuliani A, Fernández M, Gusciglio M, Pietrini V, et al. P3‐016: Chronic administration of CHF5074, a novel γ‐secretase modulator, prevents brain neurodegeneration in aged Alzheimer's disease transgenic mice. Alzheimer s & Dementia. 2011. doi:10.1016/j.jalz.2011.05.1455.
BibTeX
@article{sandra2011PChron,
title = {P3‐016: Chronic administration of CHF5074, a novel γ‐secretase modulator, prevents brain neurodegeneration in aged Alzheimer's disease transgenic mice},
author = {Sandra Sivilia and Luca Lorenzini and Alessandro Giuliani and Mercedes Fernández and Marco Gusciglio and Vladimiro Pietrini and Maria Francesca Baroc and Gino Villetti and Bruno Pietro Imbimbo and Laura Calzà and Luciana Giardino},
journal = {Alzheimer s & Dementia},
year = {2011},
doi = {10.1016/j.jalz.2011.05.1455},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2024
Open access · CC-BY
Hippocampal rejuvenation by a single intracerebral injection of one‐carbon metabolites in C57BL6 old wild‐type mice
Chronic Diseases and Translational Medicine 2018
Open access · CC-BY
Clustering of major cardiovascular risk factors is associated with arterial stiffness in adults
The Journals of Gerontology Series A 2000
Citation only
Reversible Effects of Long-Term Caloric Restriction on Protein Oxidative Damage
Brain 2016
Open access · OA
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease
Aging cell 2026
Open access · OA
In Vivo Partial Cell Reprogramming With Yamanaka Factors Reduced Ischemic Brain Damage in Aging Mice.
Life 2025
Open access · CC-BY